BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Snow JL, Kawut SM. Surrogate end points in pulmonary arterial hypertension: assessing the response to therapy. Clin Chest Med 2007;28:75-89, viii. [PMID: 17338929 DOI: 10.1016/j.ccm.2006.11.005] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 2.2] [Reference Citation Analysis]
Number Citing Articles
1 Chakinala MM, Barst R. From short-term benefits to long-term outcomes: the evolution of clinical trials in pulmonary arterial hypertension. Pulm Circ 2013;3:507-22. [PMID: 24618537 DOI: 10.1086/674456] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
2 Minai OA, Gudavalli R, Mummadi S, Liu X, Mccarthy K, Dweik RA. Heart Rate Recovery Predicts Clinical Worsening in Patients with Pulmonary Arterial Hypertension. Am J Respir Crit Care Med 2012;185:400-8. [DOI: 10.1164/rccm.201105-0848oc] [Cited by in Crossref: 56] [Cited by in F6Publishing: 22] [Article Influence: 5.6] [Reference Citation Analysis]
3 McGlinchey N, Peacock AJ. Endpoints in PAH clinical trials in the era of combination therapy: how do we decide whether something is working without going bankrupt? Drug Discov Today 2014;19:1236-40. [PMID: 24814434 DOI: 10.1016/j.drudis.2014.04.020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
4 Bradlow WM, Hughes ML, Keenan NG, Bucciarelli-Ducci C, Assomull R, Gibbs JS, Mohiaddin RH. Measuring the heart in pulmonary arterial hypertension (PAH): implications for trial study size. J Magn Reson Imaging 2010;31:117-24. [PMID: 20027579 DOI: 10.1002/jmri.22011] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 3.2] [Reference Citation Analysis]
5 Nathan SD, King CS. Treatment of pulmonary hypertension in idiopathic pulmonary fibrosis: shortfall in efficacy or trial design? Drug Des Devel Ther 2014;8:875-85. [PMID: 25061279 DOI: 10.2147/DDDT.S64907] [Cited by in Crossref: 19] [Cited by in F6Publishing: 7] [Article Influence: 2.4] [Reference Citation Analysis]
6 Krishnan U, Horn EM. A Contemporary Approach to Pulmonary Arterial Hypertension. Curr Atheroscler Rep 2016;18:58. [PMID: 27491673 DOI: 10.1007/s11883-016-0608-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
7 Weatherald J, Boucly A, Sahay S, Humbert M, Sitbon O. The Low-Risk Profile in Pulmonary Arterial Hypertension. Time for a Paradigm Shift to Goal-oriented Clinical Trial Endpoints? Am J Respir Crit Care Med 2018;197:860-8. [PMID: 29256625 DOI: 10.1164/rccm.201709-1840PP] [Cited by in Crossref: 23] [Cited by in F6Publishing: 12] [Article Influence: 7.7] [Reference Citation Analysis]
8 Gabler NB, French B, Strom BL, Liu Z, Palevsky HI, Taichman DB, Kawut SM, Halpern SD. Race and sex differences in response to endothelin receptor antagonists for pulmonary arterial hypertension. Chest 2012;141:20-6. [PMID: 21940766 DOI: 10.1378/chest.11-0404] [Cited by in Crossref: 95] [Cited by in F6Publishing: 80] [Article Influence: 8.6] [Reference Citation Analysis]
9 Parikh KS, Rajagopal S, Arges K, Ahmad T, Sivak J, Kaul P, Shah SH, Tapson V, Velazquez EJ, Douglas PS, Samad Z. Use of outcome measures in pulmonary hypertension clinical trials. Am Heart J 2015;170:419-29.e3. [PMID: 26385024 DOI: 10.1016/j.ahj.2015.06.010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
10 Göransson C, Vejlstrup N, Scheike T, Carlsen J. Implications of cardiac variability with cardiovascular magnetic resonance imaging for calculating trial sample size in pulmonary arterial hypertension. International Journal of Cardiology 2018;257:332-8. [DOI: 10.1016/j.ijcard.2017.11.020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
11 van Wolferen SA, van de Veerdonk MC, Mauritz GJ, Jacobs W, Marcus JT, Marques KMJ, Bronzwaer JGF, Heymans MW, Boonstra A, Postmus PE, Westerhof N, Vonk Noordegraaf A. Clinically significant change in stroke volume in pulmonary hypertension. Chest 2011;139:1003-9. [PMID: 20864614 DOI: 10.1378/chest.10-1066] [Cited by in Crossref: 66] [Cited by in F6Publishing: 58] [Article Influence: 5.5] [Reference Citation Analysis]
12 Sun H, Stockbridge N, Ariagno RL, Murphy D, Nelson RM, Rodriguez W. Reliable and developmentally appropriate study end points are needed to achieve drug development for treatment of pediatric pulmonary arterial hypertension. J Perinatol 2016;36:1029-33. [PMID: 27416322 DOI: 10.1038/jp.2016.103] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
13 Bonner N, Abetz L, Meunier J, Sikirica M, Mathai SC. Development and validation of the living with pulmonary hypertension questionnaire in pulmonary arterial hypertension patients. Health Qual Life Outcomes 2013;11:161. [PMID: 24088389 DOI: 10.1186/1477-7525-11-161] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
14 Ewert R, Gläser S, Opitz C. Iloprost in pulmonary hypertension. Expert Review of Respiratory Medicine 2014;2:689-702. [DOI: 10.1586/17476348.2.6.689] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
15 Rusiecki J, Rao Y, Cleveland J, Rhinehart Z, Champion HC, Mathier MA. Sex and menopause differences in response to tadalafil: 6-minute walk distance and time to clinical worsening. Pulm Circ 2015;5:701-6. [PMID: 26697177 DOI: 10.1086/683829] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
16 Minai OA, Nguyen Q, Mummadi S, Walker E, McCarthy K, Dweik RA. Heart rate recovery is an important predictor of outcomes in patients with connective tissue disease-associated pulmonary hypertension. Pulm Circ 2015;5:565-76. [PMID: 26401258 DOI: 10.1086/682432] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
17 Matura LA, McDonough A, Carroll DL. Symptom Prevalence, Symptom Severity, and Health-Related Quality of Life Among Young, Middle, and Older Adults With Pulmonary Arterial Hypertension. Am J Hosp Palliat Care 2016;33:214-21. [PMID: 25294227 DOI: 10.1177/1049909114554079] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
18 Madonna R, Cocco N, De Caterina R. Pathways and Drugs in Pulmonary Arterial Hypertension – Focus on the Role of Endothelin Receptor Antagonists. Cardiovasc Drugs Ther 2015;29:469-79. [DOI: 10.1007/s10557-015-6605-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
19 Wronski SL, Mordin M, Kelley K, Anguiano RH, Classi P, Shen E, Manaker S. The Role of Noninvasive Endpoints in Predicting Long-Term Outcomes in Pulmonary Arterial Hypertension. Lung 2020;198:65-86. [PMID: 31722043 DOI: 10.1007/s00408-019-00289-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
20 Minai OA. Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Biomarkers in pulmonary arterial hypertension. Ann Thorac Med 2014;9:S92-7. [PMID: 25077003 DOI: 10.4103/1817-1737.134047] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
21 dos Santos Fernandes CJ, Jardim CV, Hovnanian A, Hoette S, Dias BA, Souza S, Humbert M, Souza R. Survival in schistosomiasis-associated pulmonary arterial hypertension. J Am Coll Cardiol. 2010;56:715-720. [PMID: 20723801 DOI: 10.1016/j.jacc.2010.03.065] [Cited by in Crossref: 45] [Cited by in F6Publishing: 37] [Article Influence: 3.8] [Reference Citation Analysis]
22 Hummers LK. Biomarkers of vascular disease in scleroderma. Rheumatology (Oxford) 2008;47 Suppl 5:v21-2. [PMID: 18784132 DOI: 10.1093/rheumatology/ken281] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
23 Mathai SC. Solvitur ambulando…or maybe not? Chest 2013;143:285-7. [PMID: 23381304 DOI: 10.1378/chest.12-1819] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
24 Quarck R, Nawrot T, Meyns B, Delcroix M. C-Reactive Protein. Journal of the American College of Cardiology 2009;53:1211-8. [DOI: 10.1016/j.jacc.2008.12.038] [Cited by in Crossref: 147] [Cited by in F6Publishing: 134] [Article Influence: 11.3] [Reference Citation Analysis]
25 Addetia K, Bhave NM, Tabit CE, Gomberg-Maitland M, Freed BH, Dill KE, Lang RM, Mor-Avi V, Patel AR. Sample size and cost analysis for pulmonary arterial hypertension drug trials using various imaging modalities to assess right ventricular size and function end points. Circ Cardiovasc Imaging 2014;7:115-24. [PMID: 24192452 DOI: 10.1161/CIRCIMAGING.113.000932] [Cited by in Crossref: 27] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
26 Howard LS, Ferrari P, Mehta S. Physicians' and patients' expectations of therapies for pulmonary arterial hypertension: where do they meet? Eur Respir Rev 2014;23:458-68. [PMID: 25445944 DOI: 10.1183/09059180.00007514] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
27 Gabler NB, French B, Strom BL, Palevsky HI, Taichman DB, Kawut SM, Halpern SD. Validation of 6-minute walk distance as a surrogate end point in pulmonary arterial hypertension trials. Circulation 2012;126:349-56. [PMID: 22696079 DOI: 10.1161/CIRCULATIONAHA.112.105890] [Cited by in Crossref: 152] [Cited by in F6Publishing: 60] [Article Influence: 15.2] [Reference Citation Analysis]